Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Endocrinol Metab. 2011 Jul;96(7):1955-9. doi: 10.1210/jc.2011-0418. Epub 2011 Apr 20.

Seizures associated with zoledronic acid for osteoporosis.

Author information

1
Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine III, Technical University Medical Center, D-01307 Dresden, Germany.

Abstract

CONTEXT:

Bisphosphonates represent potent antiresorptive drugs that are established for therapy of patients with benign and malignant bone diseases. Zoledronic acid is an iv aminobisphosphonate that is administered annually against osteoporosis. Because of its potency and the parenteral route of administration, zoledronic acid is an alternative to oral bisphosphonates, in particular in elderly patients with multiple comorbidities. The most common side effects include an acute-phase reaction and mild and transient hypocalcemia.

OBJECTIVE:

Here, we report three cases of seizures that developed after the administration of zoledronic acid.

METHODS:

We review case histories and laboratory results of three patients with seizures associated with the administration of zoledronic acid. We discuss their course and comorbidities in the context of the published literature.

RESULTS:

All three patients were elderly persons with multiple comorbidities, including neurological diseases, that required parenteral bisphosphonates for severe osteoporosis with concurrent contraindications for oral bisphosphonates.

CONCLUSION:

We analyze potential mechanisms underlying these seizures in association with zoledronic acid exposure and discuss potential strategies to minimize this risk.

PMID:
21508139
DOI:
10.1210/jc.2011-0418
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center